Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its ...

Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Functional programming replaces mutable state and side effects with predictable, composable functions. By embracing immutability, recursion, and higher-order functions, developers can write code ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

We recently published 10 Big Names With Explosive Growth. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Wednesday. Recursion Pharmaceuticals jumped by 16.44 percent on ...

Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

During his 25 years working as a software engineer, Andy Weir wrote two novels that never found an audience. He also wrote a ...